These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19029473)

  • 21. The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3).
    Simsek C; Garcia-Garcia HM; van Geuns RJ; Magro M; Girasis C; van Mieghem N; Lenzen M; de Boer S; Regar E; van der Giessen W; Raichlen J; Duckers HJ; Zijlstra F; van der Steen T; Boersma E; Serruys PW;
    EuroIntervention; 2012 Jun; 8(2):235-41. PubMed ID: 22717926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppressive effects of standard-dose rosuvastatin therapy on the progression of coronary atherosclerosis in Japanese patients: the APOLLO study.
    Amemiya K; Yokoi H; Domei T; Shirai S; Ando K; Goya M; Iwabuchi M
    J Atheroscler Thromb; 2014; 21(12):1298-307. PubMed ID: 25100236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Daida H; Takayama T; Hiro T; Yamagishi M; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Diabetol; 2012 Jul; 11():87. PubMed ID: 22831708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 25. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(49-50):18. PubMed ID: 22308585
    [No Abstract]   [Full Text] [Related]  

  • 27. Statins and prevention of stent-related late adverse events.
    Uemura S
    Coron Artery Dis; 2014 Jun; 25(4):277-8. PubMed ID: 24710353
    [No Abstract]   [Full Text] [Related]  

  • 28. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study).
    Otagiri K; Tsutsui H; Kumazaki S; Miyashita Y; Aizawa K; Koshikawa M; Kasai H; Izawa A; Tomita T; Koyama J; Ikeda U
    Circ J; 2011; 75(3):633-41. PubMed ID: 21266787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
    Abaci O; Arat Ozkan A; Kocas C; Cetinkal G; Sukru Karaca O; Baydar O; Kaya A; Gurmen T
    Am J Cardiol; 2015 Apr; 115(7):867-71. PubMed ID: 25670636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Med could reverse arterial blockages.
    Health News; 2006 Jul; 12(7):13. PubMed ID: 16858860
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
    Link A; Ayadhi T; Böhm M; Nickenig G
    Eur Heart J; 2006 Dec; 27(24):2945-55. PubMed ID: 17012299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASTEROID--when spinning a star leads to a collision with reality.
    Jackson G
    Int J Clin Pract; 2006 May; 60(5):505. PubMed ID: 16700841
    [No Abstract]   [Full Text] [Related]  

  • 33. The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Hlatky M
    J Am Coll Cardiol; 2011 Feb; 57(7):792-3. PubMed ID: 21310314
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
    Kapur NK
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of lipid correcting therapy with the use of rosuvastatin].
    Ivleva AIa
    Kardiologiia; 2005; 45(6):71-80. PubMed ID: 16007037
    [No Abstract]   [Full Text] [Related]  

  • 37. [Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)].
    Mareev VIu
    Kardiologiia; 2008; 48(1):74-5. PubMed ID: 18261000
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):330-5. PubMed ID: 24330280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
    Mitka M
    JAMA; 2010 Apr; 303(13):1242-3. PubMed ID: 20371776
    [No Abstract]   [Full Text] [Related]  

  • 40. Cholesterol medication makes a debut in the U.S.
    Heart Advis; 2003 Oct; 6(10):2. PubMed ID: 15106543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.